Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-1593PMID 18316572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of drug combination chemosensitivity in human bladder cancer

  2007cited by this paper
• Identification and Prognostic Significance of an Epithelial-Mesenchymal Transition Expression Profile in Human Bladder Tumors

  2007cited by this paper
• Molecular correlates of gefitinib responsiveness in human bladder cancer cells

  2007cited by this paper
• Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer

  2007cited by this paper
• Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

  2006cited by this paper
• Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy

  2006cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• Erlotinib in-Previously Treated Non-Small-Cell Lung CancerShepherd FA (for the National Cancer Institute of Canada Clinical Trials Group Univ of Toronto; et al N Engl J Med 353:123-132, 2005§

  2006cited by this paper
• Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

  2006cited by this paper
• Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

  2005cited by this paper
• Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.

  2005cited by this paper
• FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC).

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Gefitinib: current and future status in cancer therapy.

  2003cited by this paper
• E-Cadherin Binding Modulates EGF Receptor Activation

  2003cited by this paper
• Summaries of Affymetrix GeneChip probe level data.

  2003cited by this paper
• Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling.

  2002cited by this paper
• Epithelial–mesenchymal transitions in tumour progression

  2002cited by this paper
• The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.

  2002cited by this paper
• Short Communication Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors

  2001cited by this paper
• Signaling from E-cadherins to the MAPK Pathway by the Recruitment and Activation of Epidermal Growth Factor Receptors upon Cell-Cell Contact Formation*

  2000cited by this paper
• Activation of the Protein Kinase Akt/PKB by the Formation of E-cadherin-mediated Cell-Cell Junctions

  1999cited by this paper
• Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.

  1995cited by this paper
• Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor

  1994cited by this paper
• A Wilcoxon-type test for trend.

  1985cited by this paper
• A Wilcoxon-type test for trend.

  1985cited by this paper
• A Coefficient of Agreement for Nominal Scales

  1960cited by this paper

• Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis

  2023cites this paper
• Cancer Stem Cells in Carcinogenesis and Potential Role in Pancreatic Cancer.

  2023cites this paper
• TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer

  2022cites this paper
• c-Met: A Promising Therapeutic Target in Bladder Cancer

  2022cites this paper
• Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation

  2022cites this paper
• Stem cell programs in cancer initiation, progression, and therapy resistance

  2020cites this paper
• Identification of chemosensitizers by drug repurposing to enhance the efficacy of cancer therapy

  2020cites this paper
• Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells.

  2019cites this paper
• Role of the Nuclear Receptor PPARγ in Clear Cell Renal and Bladder Urotheial Carcinoma

  2019cites this paper
• Clinical and molecular characteristics of bladder urothelial carcinoma subtypes

  2018cites this paper
• Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer

  2018cites this paper
• Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

  2018cites this paper
• Gelatin nonwovens-based epithelial morphogenesis involves a signaling axis comprising EGF-receptor, MAP kinases ERK 1/2, and β1 integrin.

  2018cites this paper
• ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer

  2017cites this paper
• EGFR family inhibition identifies p 38 MAPK as a potential therapeutic target in bladder cancer

  2017cites this paper
• Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.

  2017cites this paper
• Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.

  2017cites this paper
• The Response of Cancer Cell Populations to Therapies

  2017cites this paper
• Preclinical Characterization of CTL-1, A Biosimilar Anti-EGFR Monoclonal Antibody for Cetuximab

  2017cites this paper
• TET1 promotes cisplatin‐resistance via demethylating the vimentin promoter in ovarian cancer

  2017cites this paper
• Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy

  2016cites this paper
• Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.

  2016cites this paper
• Association of thymosin β4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients.

  2016cites this paper
• Invasion Mechanisms of Bladder Cancer: A Molecular Review

  2016cites this paper
• The role of epithelial mesenchymal transition transcription factors on DNA damage response

  2016cites this paper
• Origins of Bladder Cancer.

  2016cites this paper
• Epithelial plasticity in urothelial carcinoma: Current advancements and future challenges.

  2016cites this paper
• SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin

  2016cites this paper
• Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells

  2016cites this paper
• Recreating complex pathophysiologies in vitro with extracellular matrix surrogates for anticancer therapeutics screening.

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer

  2016cites this paper
• Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion

  2016cites this paper
• Epithelial to Mesenchymal Transition in a Clinical Perspective

  2015cites this paper
• Molecular Biology of Urothelial Cancer

  2015cites this paper
• Genetic subtypes of invasive bladder cancer

  2015cites this paper
• The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.

  2015cites this paper
• Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.

  2015cites this paper
• Investigation of approaches for overcoming chemoresistance in pancreatic cancer

  2014cites this paper
• Effects of 4-(3-Chloro-Benzyl)-6,7- Dimethoxy-Quinazoline on Kinetics of P120- Catenin and Periplakin in Human Buccal Mucosa Squamous Carcinoma Cell Line

  2014cites this paper
• Untersuchungen des EGF-Rezeptor-Signalwegs als molekulare Zielstruktur zur Behandlung des Magenkarzinoms

  2014cites this paper
• Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells

  2014cites this paper
• Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

  2014cites this paper
• Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.

  2014cites this paper
• Research on chemotherapy efficacy of twist gene on cervical cancer cells to paclitaxel.

  2014cites this paper
• New Treatments for Bladder Cancer: When Will We Make Progress?

  2014cites this paper
• Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

  2014cites this paper
• A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

  2014cites this paper
• Chirurgische Klinik und Hochschulambulanz I Allgemein-, Viszeral- und Gef äß chirurgie der Medizinischen Fakult ä t Charit é - Universit ä tsmedizin Berlin

  2014cites this paper
• MicroRNA-21 inhibitor potentiates anti-tumor effect of radiation therapy in vitro and in vivo

  2014cites this paper
• MECHANISMS UNDERLYING DISTINCT EGFR VERSUS FGFR-3 AND -1 DEPENDENCY IN HUMAN BLADDER CANCER CELLS

  2014cites this paper
• Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

  2013cites this paper
• The role of E-cadherin in EGFR signal transduction and EGFR-inhibitory treatment in gastric cancer

  2013cites this paper
• Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.

  2013cites this paper
• Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting

  2013cites this paper
• Identification of Tumor Cell- and Stroma Derived Biomarkers of Treatment Response in Head and Neck Cancer

  2013cites this paper
• Molecular targets on the horizon for kidney and urothelial cancer

  2013cites this paper
• Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer

  2013cites this paper
• The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer

  2013cites this paper
• Targeting the Epidermal Growth Factor Receptor in Bladder Cancer

  2013cites this paper
• Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target

  2013cites this paper
• Molecular Classification of Bladder Cancer

  2013cites this paper
• Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

  2013cites this paper
• miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.

  2013cites this paper
• Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

  2013cites this paper
• Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

  2013cites this paper
• Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.

  2012cites this paper
• Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma

  2012cites this paper
• p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers

  2012cites this paper
• Stem cells in squamous head and neck cancer.

  2012cites this paper
• Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines

  2012cites this paper
• Current Preclinical Models for the Advancement of Translational Bladder Cancer Research

  2012cites this paper
• Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

  2012cites this paper
• Emerging therapies for urothelial cancer.

  2012cites this paper
• Cadherin Expression and Progression of Squamous Cell Carcinomas of the Oral Cavity

  2012cites this paper
• Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation

  2012cites this paper
• Tumorigenesis and Neoplastic Progression Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200 c and miR-205

  2012cites this paper
• Molecular signaling and the role of targeted therapies in bladder cancer.

  2012cites this paper
• Bladder Cancer and Cancer Stem Cells: Basic Science and Implications for Therapy

  2011cites this paper
• Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

  2011cites this paper
• E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression

  2011cites this paper
• A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT

  2011cites this paper
• Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer

  2011cites this paper
• E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models

  2011cites this paper
• Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.

  2011cites this paper
• Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis.

  2011cites this paper
• Urothelial carcinomas: a focus on human epidermal receptors signaling.

  2011cites this paper
• Author Summary: Abstract and Brief Discussion

  2011cites this paper
• The Pennsylvania State University The Graduate School Intercollege Graduate Degree Program in Genetics EXPRESSION AND FUNCTION OF THE TUMOR SUPPRESSOR CANDIDATE HTRA1 IN HUMAN BREAST EPITHELIAL CELLS

  2011cites this paper
• PURINERGIC SIGNALING REGULATES FILOPODIA-INDUCED ZIPPERING

  2011cites this paper
• microRNAs and EMT in Mammary Cells and Breast Cancer

  2010cites this paper
• Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

  2010cites this paper
• Imaging , Diagnosis , Prognosis Expression of Snail in Upper Urinary Tract Urothelial Carcinoma : Prognostic Significance and Implications for Tumor Invasion

  2010cites this paper
• Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.

  2010influential citation
• Tumour-microenvironmental interactions: paths to progression and targets for treatment.

  2010cites this paper
• Bladder Cancer: Can We Move Beyond Chemotherapy?

  2010cites this paper
• VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.

  2010cites this paper
• Inhibidores de la tirosin-quinasa en el tratamiento del cáncer de vejiga músculo-infiltrante y el cáncer de próstata hormono-refractario

  2010cites this paper
• Molecular Characterization of Pancreatic Cancer Cell Lines

  2010cites this paper
• A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment

  2010cites this paper
• Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

  2009cites this paper